Biohaven Pharmaceutical Holding Co. Ltd.
(NYSE : BHVN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 6.75%131.470.7%$2064.77m
PFEPfizer Inc. 2.33%31.620.9%$1465.21m
MRKMerck & Co., Inc. 5.34%75.560.7%$1362.61m
ABBVAbbVie, Inc. 2.81%74.712.3%$1247.19m
BMYBristol-Myers Squibb Co. 2.55%54.141.0%$1089.88m
LLYEli Lilly & Co. 2.56%137.541.1%$919.33m
FTSVForty Seven, Inc. 0.88%95.380.0%$327.50m
NVSNovartis AG 2.18%81.010.2%$320.73m
GSKGlaxoSmithKline Plc 1.87%37.120.2%$281.80m
AZNAstraZeneca Plc 3.47%43.951.2%$277.68m
NVONovo Nordisk A/S 4.95%59.540.1%$175.10m
SNYSanofi 5.02%44.570.2%$166.29m
BHCBausch Health Cos., Inc. -0.75%14.400.0%$103.36m
RGENRepligen Corp. 2.81%95.157.1%$74.52m
RETAReata Pharmaceuticals, Inc. 2.35%153.523.4%$69.11m

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.